Attune Medical said today it closed a $15.5 million oversubscribed Series C round of financing,.
Funds from the round are slated to support expansion and progression of the company’s temperature management technology, including its flagship EnsoETM esophageal cooling device.
The EnsoETM is designed to control patient temperature through a system inserted into the esophagus, which uses two lumens attached to an external heat exchange and a third lumen to allow for gastric decompression and drainage. The system also features a standard gastric tube and can be used in emergency rooms, operating rooms, recovery rooms and intensive care units, the company said.
“As the clinical use of temperature management gains a broader worldwide footprint in healthcare overall, Attune will continue to expand the application base for the EnsoETM toward novel, clinically impactful uses across a diverse array of clinical settings. We are well-positioned for continued growth in the critical care space, while also pursuing clinical evidence in support of new applications positioned to bring increased safety and efficacy to operating rooms and electrophysiology labs. This oversubscribed fundraising is a concrete signal of investor and market confidence in our mission to make temperature management as accessible and useful as possible for all clinical applications and patients who can benefit from this therapy,” Attune CEO Keith Warner said in a press release.
In January, Attune Medical said that it won 510(k) clearance from the FDA for a new model of its EnsoETM device capable of administering tube feeds or medication while regulating a patient’s temperature through the esophagus.